Emergent BioSolutions Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Emergent BioSolutions Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $742.90M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.04B | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $1.05B | Feb 27, 2026 |
| FY2022 | Dec 31, 2022 | $330.20M | Dec 11, 2023 |
| FY2022 | Sep 30, 2022 | $239.90M | Dec 11, 2023 |
| FY2022 | Jun 30, 2022 | $242.60M | Dec 11, 2023 |
| FY2022 | Mar 31, 2022 | $304.80M | Dec 11, 2023 |
| FY2022 | Dec 31, 2021 | $732.90M | Dec 11, 2023 |
| FY2022 | Sep 30, 2021 | $286.30M | Dec 11, 2023 |
| FY2022 | Jun 30, 2021 | $377.40M | Dec 11, 2023 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $742.90M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.04B | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $1.05B | Feb 27, 2026 |
| FY2020 | Dec 31, 2020 | $583.00M | Feb 19, 2021 |
| FY2020 | Sep 30, 2020 | $385.20M | Feb 19, 2021 |
| FY2020 | Jun 30, 2020 | $394.70M | Feb 19, 2021 |
| FY2020 | Mar 31, 2020 | $192.50M | Feb 19, 2021 |
| FY2020 | Dec 31, 2019 | $360.40M | Feb 19, 2021 |
| FY2020 | Sep 30, 2019 | $311.80M | Feb 19, 2021 |
| FY2020 | Jun 30, 2019 | $243.20M | Feb 19, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $193.81M | Feb 23, 2018 |
| FY2017 | Sep 30, 2017 | $149.43M | Feb 23, 2018 |
| FY2017 | Jun 30, 2017 | $100.77M | Feb 23, 2018 |
| FY2017 | Mar 31, 2017 | $116.86M | Feb 23, 2018 |
| FY2017 | Dec 31, 2016 | $151.66M | Feb 23, 2018 |
| FY2017 | Sep 30, 2016 | $142.91M | Feb 23, 2018 |
| FY2017 | Jun 30, 2016 | $91.24M | Feb 23, 2018 |
| FY2017 | Mar 31, 2016 | $102.96M | Feb 23, 2018 |
| FY2016 | Dec 31, 2015 | $159.78M | Feb 28, 2017 |
| FY2016 | Sep 30, 2015 | $158.38M | Feb 28, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $317.60M | Mar 8, 2024 |
| FY2023 | Dec 31, 2022 | $383.00M | Mar 8, 2024 |
| FY2023 | Dec 31, 2021 | $891.30M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $925.20M | Dec 11, 2023 |
| FY2019 | Dec 31, 2019 | $77.80M | Feb 25, 2020 |
| FY2019 | Sep 30, 2019 | $70.70M | Feb 25, 2020 |
| FY2019 | Jun 30, 2019 | ($7.00M) | Feb 25, 2020 |
| FY2019 | Mar 31, 2019 | ($27.40M) | Feb 25, 2020 |
| FY2019 | Dec 31, 2018 | $11.20M | Feb 25, 2020 |
| FY2019 | Sep 30, 2018 | $21.30M | Feb 25, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.60M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($190.60M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($760.50M) | Feb 27, 2026 |
| FY2022 | Dec 31, 2022 | ($67.00M) | Dec 11, 2023 |
| FY2022 | Sep 30, 2022 | ($87.10M) | Dec 11, 2023 |
| FY2022 | Jun 30, 2022 | ($52.90M) | Dec 11, 2023 |
| FY2022 | Mar 31, 2022 | ($4.60M) | Dec 11, 2023 |
| FY2022 | Dec 31, 2021 | $193.10M | Dec 11, 2023 |
| FY2022 | Sep 30, 2021 | ($40.40M) | Dec 11, 2023 |
| FY2022 | Jun 30, 2021 | ($500.0K) | Dec 11, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $100.10M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($108.70M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($726.40M) | Feb 27, 2026 |
| FY2022 | Dec 31, 2022 | ($55.30M) | Dec 11, 2023 |
| FY2022 | Sep 30, 2022 | ($45.30M) | Dec 11, 2023 |
| FY2022 | Jun 30, 2022 | ($76.30M) | Dec 11, 2023 |
| FY2022 | Mar 31, 2022 | $6.90M | Dec 11, 2023 |
| FY2022 | Dec 31, 2021 | $286.80M | Dec 11, 2023 |
| FY2022 | Sep 30, 2021 | ($44.70M) | Dec 11, 2023 |
| FY2022 | Jun 30, 2021 | $7.10M | Dec 11, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.20M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $70.70M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $111.40M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $188.30M | Mar 4, 2025 |
| FY2023 | Dec 31, 2021 | $235.20M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $237.90M | Dec 11, 2023 |
| FY2021 | Dec 31, 2019 | $226.20M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $142.80M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $97.40M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $106.90M | Feb 22, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $186.10M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $308.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $368.40M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $339.50M | Mar 4, 2025 |
| FY2023 | Dec 31, 2021 | $348.70M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $304.10M | Dec 11, 2023 |
| FY2021 | Dec 31, 2019 | $273.50M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $202.50M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $142.90M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $143.10M | Feb 22, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $170.60M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $58.70M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($206.30M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($34.10M) | Mar 4, 2025 |
| FY2023 | Dec 31, 2021 | $320.20M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $536.90M | Dec 11, 2023 |
| FY2021 | Dec 31, 2019 | $188.00M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $41.80M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $208.10M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $54.60M | Feb 22, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.80M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $22.90M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $51.60M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $115.80M | Mar 4, 2025 |
| FY2023 | Dec 31, 2021 | $224.10M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $141.90M | Dec 11, 2023 |
| FY2021 | Dec 31, 2019 | $86.90M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $72.10M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $54.80M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $76.20M | Feb 22, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.32B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.39B | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $1.82B | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $3.17B | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $2.96B | Dec 11, 2023 |
| FY2021 | Dec 31, 2020 | $2.88B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $2.33B | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $2.23B | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $1.07B | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $970.11M | Feb 23, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $796.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $906.90M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $1.17B | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $1.78B | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $1.35B | Dec 11, 2023 |
| FY2021 | Dec 31, 2020 | $1.44B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $1.24B | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $1.22B | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $157.90M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $373.91M | Feb 23, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $522.60M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $482.80M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $649.30M | Feb 27, 2026 |
| FY2025 | Dec 31, 2022 | $1.39B | Feb 27, 2026 |
| FY2024 | Dec 31, 2021 | $1.61B | Mar 4, 2025 |
| FY2023 | Dec 31, 2020 | $1.45B | Mar 8, 2024 |
| FY2022 | Dec 31, 2019 | $1.09B | Dec 11, 2023 |
| FY2021 | Dec 31, 2018 | $1.01B | Feb 25, 2022 |
| FY2020 | Dec 31, 2017 | $912.30M | Feb 19, 2021 |
| FY2019 | Dec 31, 2016 | $596.20M | Feb 25, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $0 | Feb 27, 2026 |
| FY2023 | Dec 31, 2022 | $218.20M | Mar 8, 2024 |
| FY2023 | Dec 31, 2021 | $224.90M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $266.70M | Dec 11, 2023 |
| FY2020 | Dec 31, 2019 | $266.60M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $259.70M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $49.10M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $41.00M | Feb 23, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($159.80M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($212.40M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($21.80M) | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $738.70M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $950.30M | Dec 11, 2023 |
| FY2021 | Dec 31, 2020 | $726.90M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $421.80M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $367.30M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $337.10M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $254.48M | Feb 23, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $205.40M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $99.50M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $111.70M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $642.60M | Mar 4, 2025 |
| FY2022 | Dec 31, 2021 | $576.10M | Dec 11, 2023 |
| FY2022 | Dec 31, 2020 | $621.30M | Dec 11, 2023 |
| FY2021 | Dec 31, 2019 | $167.80M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $112.20M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $178.30M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $271.50M | Feb 22, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $589.70M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $700.00M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $868.40M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $1.41B | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $849.60M | Dec 11, 2023 |
| FY2021 | Dec 31, 2020 | $885.50M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $822.50M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $808.80M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $13.60M | Feb 22, 2019 |
| FY2013 | Dec 31, 2013 | $62.00M | Mar 10, 2014 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | (14) | Feb 27, 2026 |
| FY2022 | Dec 31, 2022 | (1) | Dec 11, 2023 |
| FY2022 | Sep 30, 2022 | (1) | Dec 11, 2023 |
| FY2022 | Jun 30, 2022 | (1) | Dec 11, 2023 |
| FY2022 | Mar 31, 2022 | 0 | Dec 11, 2023 |
| FY2022 | Dec 31, 2021 | 3 | Dec 11, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Dec 11, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Dec 11, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | (14) | Feb 27, 2026 |
| FY2022 | Dec 31, 2022 | (1) | Dec 11, 2023 |
| FY2022 | Sep 30, 2022 | (1) | Dec 11, 2023 |
| FY2022 | Jun 30, 2022 | (1) | Dec 11, 2023 |
| FY2022 | Mar 31, 2022 | 0 | Dec 11, 2023 |
| FY2022 | Dec 31, 2021 | 3 | Dec 11, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Dec 11, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Dec 11, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 52.10M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 54.30M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 52.20M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | 50.10M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | 51.30M | Dec 11, 2023 |
| FY2021 | Dec 31, 2020 | 53.10M | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | 51.70M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | 51.20M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | 49.40M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | 40.57M | Feb 23, 2018 |